APA (7th ed.) Citation

EF, M., M, D., J, S., DR, P., VP, W., J, W., . . . R, F. (2026). Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: Findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial. Lancet (London, England), 407(10541), 1809. https://doi.org/10.1016/S0140-6736(26)00463-0

Chicago Style (17th ed.) Citation

EF, Morand, et al. "Enpatoran, a Toll-like Receptor 7/8 Inhibitor, in Moderate-to-severe Systemic Lupus Erythematosus: Findings from Cohort B of a Multicentre, International, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial." Lancet (London, England) 407, no. 10541 (2026): 1809. https://doi.org/10.1016/S0140-6736(26)00463-0.

MLA (9th ed.) Citation

EF, Morand, et al. "Enpatoran, a Toll-like Receptor 7/8 Inhibitor, in Moderate-to-severe Systemic Lupus Erythematosus: Findings from Cohort B of a Multicentre, International, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial." Lancet (London, England), vol. 407, no. 10541, 2026, p. 1809, https://doi.org/10.1016/S0140-6736(26)00463-0.